SILO PHARMA, INC. Other Selling, General and Administrative Expense
SILO PHARMA, INC. (SILO) reported Other Selling, General and Administrative Expense of $96.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherSellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- SILO PHARMA, INC. other selling, general and administrative expense for the quarter ending 2026-06-30 was $96.00K, a 81.23% increase year-over-year.
- SILO PHARMA, INC. other selling, general and administrative expense for the quarter ending 2026-03-31 was $80.81K, a 25.41% increase year-over-year.
- SILO PHARMA, INC. other selling, general and administrative expense for the quarter ending 2025-12-31 was $76.44K, a 27.19% increase year-over-year.
- SILO PHARMA, INC. other selling, general and administrative expense for the quarter ending 2025-09-30 was $64.86K, a 19.37% decline year-over-year.
| Period end | Other Selling, General and Administrative Expense 3 month | Other Selling, General and Administrative Expense 6 month | Other Selling, General and Administrative Expense 9 month | Other Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $96.00K 10-Q · filed 2026-08-13 | $176.81K 10-Q · filed 2026-08-13 | $253.25K derived: sum of 3 quarters · filed 2026-08-13 | $318.11K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $80.81K 10-Q · filed 2026-05-14 | $157.25K derived: sum of 2 quarters · filed 2026-05-14 | $222.11K derived: sum of 3 quarters · filed 2026-05-14 | $275.08K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $76.44K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $141.30K derived: sum of 2 quarters · filed 2026-04-14 | $194.28K derived: sum of 3 quarters · filed 2026-08-13 | $258.71K POS AM · filed 2026-04-14 |
| 2025-09-30 | $64.86K 10-Q · filed 2025-11-13 | $117.84K derived: sum of 2 quarters · filed 2026-08-13 | $182.27K 10-Q · filed 2025-11-13 | $242.37K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $52.97K 10-Q · filed 2026-08-13 | $117.41K 10-Q · filed 2026-08-13 | $177.50K derived: sum of 3 quarters · filed 2026-08-13 | $257.95K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $64.43K 10-Q · filed 2026-05-14 | $124.53K derived: sum of 2 quarters · filed 2026-05-14 | $204.98K derived: sum of 3 quarters · filed 2026-05-14 | $276.65K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $60.10K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $140.55K derived: sum of 2 quarters · filed 2026-04-14 | $212.22K derived: sum of 3 quarters · filed 2026-04-14 | $298.28K POS AM · filed 2026-04-14 |
| 2024-09-30 | $80.45K 10-Q · filed 2025-11-13 | $152.12K derived: sum of 2 quarters · filed 2025-11-13 | $238.19K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $71.67K 10-Q · filed 2025-08-13 | $157.74K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $86.07K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |